Top Institutions in Breast Oncology and Molecular Diagnostics
Leading institutions employ prospective clinical trials integrating liquid biopsy technologies such as ctDNA assays with traditional imaging and pathology to personalize breast cancer treatment, especially in elderly populations. These centers combine expertise in molecular diagnostics, oncology, and geriatric care to validate ctDNA as a tool for treatment stratification and monitoring.
-
#1
Memorial Sloan Kettering Cancer Center
New York, NY
MSKCC is a pioneer in liquid biopsy research and clinical trials integrating ctDNA analysis for breast cancer management, with strong programs in personalized oncology and elderly patient care.
Key Differentiators
- Breast Oncology
- Molecular Diagnostics
- Geriatric Oncology
-
#2
Dana-Farber Cancer Institute
Boston, MA
Dana-Farber has extensive expertise in breast cancer clinical trials and molecular biomarker development, including ctDNA assays, with a focus on improving outcomes in older adults.
Key Differentiators
- Breast Oncology
- Molecular Pathology
- Translational Cancer Research
-
#3
MD Anderson Cancer Center
Houston, TX
MD Anderson leads in clinical implementation of liquid biopsy technologies and personalized treatment approaches in breast cancer, including studies focused on elderly populations.
Key Differentiators
- Breast Cancer Research
- Liquid Biopsy
- Clinical Oncology
-
#4
Johns Hopkins University
Baltimore, MD
Johns Hopkins has contributed significantly to the development of ctDNA technologies and their application in breast cancer, with a focus on integrating molecular data into clinical practice.
Key Differentiators
- Molecular Oncology
- Breast Cancer
- Liquid Biopsy Research
-
#5
University of California, San Francisco (UCSF)
San Francisco, CA
UCSF is recognized for its research on personalized cancer care and the use of liquid biopsies to guide treatment in elderly breast cancer patients.
Key Differentiators
- Breast Oncology
- Molecular Diagnostics
- Geriatric Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Newsletters
Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.
